CXCL8 and neoplasm: One had ongoing stable disease for more than 18 months; interestingly, one additional patient had a brief, but marked, tumour regression (73%) accompanied by significant increases (4- to 35-fold) in serum cytokine levels( IL-6, IL-8, IL-10, and IL-1 receptor antagonists).